Unlimited Bio has produced four genetic therapy constructs for an upcoming mouse experiment scheduled to begin in two weeks. Each construct targets a distinct biological pathway:
To our knowledge, no research team has ever tested three or more genetic therapies simultaneously in a single preclinical study. This effort underscores that humanity remains at the dawn of combinatorial gene therapy research.
- VEGF (Vascular Endothelial Growth Factor): a master regulator of angiogenesis that drives new blood vessel growth to improve tissue oxygen and nutrient delivery.
- Follistatin: a potent inhibitor of activin and myostatin that lifts inhibitory signals on muscle cells, resulting in enhanced hypertrophy.
- Klotho: a longevity-associated protein acting as a co-receptor for FGF23 to maintain mineral balance while modulating oxidative stress and age-related signaling.
- BDNF (Brain-Derived Neurotrophic Factor): essential for neuron survival and synaptic plasticity, BDNF supports learning, memory and recovery in models of neurodegeneration.
To our knowledge, no research team has ever tested three or more genetic therapies simultaneously in a single preclinical study. This effort underscores that humanity remains at the dawn of combinatorial gene therapy research.